Select

Assessing Solid Tumour Cancer Progression

Technology Overview

A set of biomarkers and method for assessing cancer progression in solid tumour cancers such as breast, lung & colorectal

Receptor tyrosine kinases (RTKs) are critical regulators of many cellular processes, including proliferation, differentiation, cell cycle control, metabolism, cell migration and invasion.

Diseases as diverse as diabetes and cancer have causal links to mutations in RTKs or their aberrant expression, localisation or regulation. The points of control of RTK signalling can roughly be divided into where it receives signal and where it transmits the signal that has been received.

Signal reception occurs at the extracellular side of the plasma membrane whereas signal transmission occurs at multiple sites intracellularly.

The amount of RTK on the cell surface determines the amount of signal that can be received and the duration of signal reception when ligand is abundantly available. The amount of RTKs on the cell surface is, in turn, determined by the rate of delivery of newly synthesised RTK to the plasma membrane, the rate of internalisation (endocytosis) and the rate of recycling. Being able to monitor or have control or regulate endosomal trafficking will be of benefit in terms of downstream signalling and cell growth as part of metastasis of certain cancers.

Technology Features & Specifications

A method of assessing progression of a cancer disease (solid tumour such as breast, lung, colorectal, lung etc.) associated with an increase or undesired receptor tyrosine kinase activity.

The method comprising assessing endosomal recycling of the RTK, wherein increased endosomal recycling of the RTK is indicative of the cancer disease changing from a less progressed stage to a more progressed stage. We have several additional markers that are indicative of endosomal recycling (increased or decreased).

Potential Applications

The technology has use The technology has use in the cancer therapeutic and prognostic field, and would benefit pharmaceutical companies marketing certain oncology therapies.in the cancer therapeutic and prognostic field, and would benefit pharmaceutical companies marketing certain oncology therapies.

Customer Benefits

A set of biomarkers and method for assessing cancer progression in solid tumour cancers such as breast, lung & colorectal

Make an Enquiry